Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Viatris Inc.NASDAQ: VTRS

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit growth accelerates

Q2 FY2026 gross profit of $1.46B rose 9.3% year over year, ahead of the -0.7% change in trailing-twelve-month gross profit. Sequentially, it rose 25.9% from the prior quarter. Over 3 fiscal years it compounded at -8.3% a year.

Context

  • Gross profit amounted to 35.1% of revenue in FY2025, down 3.1 pp from a year earlier.
  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +9.3% holds above the trailing-twelve-month pace of -0.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.46B+25.9% QoQ
Last fiscal yearDec 2025
$5.01B-10.8% YoY
LTMJun 2026
$5.13B-0.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.3%——
1 year-10.8%——
3-year CAGR-8.3%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
5.01B USD
Year-over-year change
-10.8%
4-year CAGR
-2.6%

Gross Profit vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.7% is the 6th highest of 9, against a peer median of +10.6%.
  • Gross profit amounts to 34.8% of revenue for VTRS, versus a peer median of 53.4%.
VTRS Competitors
Gross Profit for VTRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹163.93B INR-15.1%+10.2%49.5%
HLNHaleon plcLTM Jun 2025£10.45B GBP—+2.0%63.2%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$9.09B USD+10.2%+8.6%52.5%
BHCBausch Health Companies Inc.LTM Jun 2026$7.8B USD+11.8%+8.0%71.8%
VTRSViatris Inc.LTM Jun 2026$5.13B USD-0.7%-8.3%34.8%
OGNOrganon & Co.LTM Sep 2026$3.26B USD-6.1%-4.7%53.4%
ALKSAlkermes plcLTM Sep 2026$1.45B USD+11.0%+12.7%82.9%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$1.23B USD+14.1%+12.8%39.3%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$609.07M USD+52.3%+36.4%65.9%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$341.13M USD-7.6%+12.7%47.3%
Peer median (excluding VTRS) —+10.6%+10.2%53.4%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.89B16.26B15.43B14.74B14.3B
Cost of Revenue12.31B9.77B8.99B9.12B9.29B
Gross Profit5.58B6.5B6.44B5.62B5.01B
Gross Margin31.2%40.0%41.7%38.2%35.1%
Research & Development681M662.2M805.2M808.7M965.9M
Selling, General & Admin4.53B4.18B4.65B4.43B3.79B
Operating Expenses5.61B4.88B5.67B5.61B7.68B
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
EBITDA4.48B6.43B3.52B2.64B(395.4M)
EBITDA Margin25.0%39.6%22.8%17.9%-2.8%
Operating Income(34M)1.61B766.2M10.1M(2.66B)
Operating Margin-0.2%9.9%5.0%0.1%-18.6%
Interest Income00000
Interest Expense636.2M592.4M573.1M550M471.3M
Other Income / Expenses(630.4M)1.2B(563.3M)(633.3M)(1B)
Income Before Tax(664.4M)2.81B202.9M(623.2M)(3.67B)
Pre-Tax Margin-3.7%17.3%1.3%-4.2%-25.6%
Income Tax Expense604.7M734.6M148.2M11M(150.1M)
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Net Margin-7.1%12.8%0.4%-4.3%-24.6%
EPS (Basic)(1.05)1.710.05(0.53)(3.00)
EPS (Diluted)(1.05)1.710.05(0.53)(3.00)
Weighted Avg Shares1.21B1.21B1.2B1.19B1.17B
Weighted Avg Shares (Diluted)1.21B1.22B1.21B1.19B1.17B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.